$ALDX

Aldeyra Therapeutics, Inc.

CIK:0001341235|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 3,484,514	$ 8,505,229	$ 5,894,089	$ 15,928,552
General and administrative	2,365,993	1,663,503	3,503,336	4,667,639
Loss from operations	(5,850,507)	(10,168,732)	(9,397,425)	(20,596,191)
Other income (expense):
Interest income	400,257	872,038	963,235	1,853,525
Interest expense	(23)	(470,618)	(468,702)	(954,147)
Total other income, net	400,234	401,420	494,533	899,378
Net loss	$ (5,450,273)	$ (9,767,312)	$ (8,902,892)	$ (19,696,813)
Net loss per share - basic	$ (0.09)	$ (0.16)	$ (0.15)	$ (0.33)
Net loss per share - diluted	$ (0.09)	$ (0.16)	$ (0.15)	$ (0.33)
Weighted average common shares outstanding - basic	60,321,068	60,045,530	60,320,184	59,966,841
Weighted average common shares outstanding - diluted	60,321,068	60,045,530	60,320,184	59,966,841

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,902,892)	$ (19,696,813)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	655,447	2,420,578
Non-cash interest expense	50,368	117,525
Net amortization of premium on marketable securities	0	(838,915)
Depreciation and amortization expense	137,305	123,194
Write-off of deferred offering costs	0	267,261
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(546,918)	708,358
Accounts payable	(20,985)	849,077
Accrued expenses and other liabilities	(1,071,836)	(4,975,186)
Net cash used in operating activities	(9,699,511)	(21,024,921)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of fixed assets	(23,097)	0
Purchases of marketable securities	0	(40,263,712)
Maturities of marketable securities	0	47,000,000
Net cash (used in) provided by investing activities	(23,097)	6,736,288
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	71,140	983,194
Proceeds from employee stock purchase plan	0	19,616
Repayment of long-term debt	(15,000,000)	0
Debt end of term charge paid in cash	(300,000)	0
Net cash provided by (used in) financing activities	(15,228,860)	1,002,810
NET DECREASE IN CASH AND CASH EQUIVALENTS	(24,951,468)	(13,285,823)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	70,041,254	54,527,092
CASH AND CASH EQUIVALENTS, END OF PERIOD	45,089,786	41,241,269
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest	559,625	841,750
SUPPLEMENTAL INFORMATION AND DISCLOSURES OF NONCASH ACTIVITIES:
Change in right-of-use asset and lease liability due to lease amendment	$ 0	$ 260,899

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 45,089,786	$ 70,041,254
Prepaid expenses and other current assets	2,289,120	1,742,202
Total current assets	47,378,906	71,783,456
Fixed assets, net	20,544	0
Right-of-use assets	141,109	275,861
Total assets	47,540,559	72,059,317
Current liabilities:
Accounts payable	137,476	158,461
Accrued expenses	3,374,333	6,120,297
Current portion of debt	0	15,249,632
Operating lease liabilities	143,447	280,537
Deferred collaboration revenue	6,000,000	6,000,000
Operating lease liabilities, long-term	0
Total current liabilities	9,655,256	27,808,927
Total liabilities	9,655,256	27,808,927
Commitments and contingencies (Notes 3, 9, & 13)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding	0	0
Common stock, voting, $0.001 par value; 150,000,000 authorized and 60,321,068 and 60,162,773 shares issued and outstanding, respectively	60,321	60,163
Additional paid-in capital	530,685,127	528,147,480
Accumulated deficit	(492,860,145)	(483,957,253)
Total stockholders’ equity	37,885,303	44,250,390
Total liabilities and stockholders’ equity	$ 47,540,559	$ 72,059,317